Media logo
Local 10 News

New device offers alternative for migraine relief

Recent research is showing that a non-systemic treatment can provide relief from migraine headaches, which affect an estimated 12% of Americans. Dr. Teshamae Monteith is an associate professor of clinical neurology and chief of the headache division at the University of Miami Health System. Monteith said a study involving adolescents found that an app-controlled neuromodulation […]
Fox News

17-year-old finds miracle migraine treatment at Kansas City hospital

A teenager and her mom are driving more than 300 miles from Arkansas to Kansas City for what they call a miracle treatment. With migraines so bad that 17-year-old Sonja Burnett said she could barely walk anymore, every single mile of the trek will be worth it. After nearly 4 years of not leaving her […]
practical pain management logo
Practical Pain management

Nerivio Gets FDA Nod for Use in Migraine Prevention

The FDA has approved Nerivio as a preventive treatment for migraine, with or without aura, in adults and children 12 years old and older. The non-invasive prescription wearable had already been approved as a treatment for acute migraine in adolescents and adults. The device’s dual-use approval opens up new options for migraine care in adolescents and adults.
Fierce Biotech

Theranica aims to stretch FDA nod with study of neuromodulation device as preventive migraine treatment

With almost two more years having passed since the company successfully lobbied the FDA to expand its Nerivio neuromodulation armband indication as an acute migraine treatment from adults only to all patients aged 12 and older with episodic or chronic migraine, Theranica is once again asking the agency to expand the device’s approved usage. Its […]
Health Tech World logo
Health Tech World

NewsInterview: The drug-free migraine treatment that’s got big pharma worried

Theranica says it has demonstrated clinical evidence equivalent to commonly prescribed medications and serves more than 25,000 people with migraine, including adolescents and adults, in the USA. Health Tech World speaks with Alon Ironi, CEO of Theranica, to learn more about the wearable that’s got big pharmaceutical companies worried.
Channel 3 Eyewitness News

Wireless Nerivio Helps Manage Migraines

Connecticut’s Channel 3 Eyewitness News segment focus on the Nerivio device for easing migraine pain. Dr. Brian Grosberg, medical director of the HHC headache program at Hartford healthcare CT, explains the mechanism and benefits of Nerivio.
MedCity News

Moving beyond one-dose-fits-all: How medtech and personalized dosing can improve outcomes

Several medical devices using electrical neuromodulation have been developed to treat pain, spinal injuries, epilepsy, migraine, and other conditions. More than just a new technological solution, the possibility presented by these devices is significant.
migraine treatment options illustration

Real-World Experience with Nerivio

Tom Picerno, formally diagnosed with chronic migraine, tells about his experience with Nerivio: "...I find it comforting to know that I have non-drug related therapies in my arsenal of migraine care options. I know for me it has been used effectively to replace my abortive triptans..."
AIPAC engage learn.connect.advocate.
The American Israel Public Affairs Committee

AIPAC Briefing: Treating Migraines Digitally

Theranica CEO Alon Ironi explains how his innovative technology, Nerivio, alleviates migraines and other ailments—all without the use of prescription drugs. Theranica is an Israeli biomedical technology company.
physician weekly logo
Physician's Weekly

REN: A Novel Approach to Migraine Treatment

Evidence suggests that pharmacologic agents often used to treat migraine may at times be ineffective, poorly tolerated, contraindicated, and—if used too frequently—can cause possible medication overuse headache, migraine chronification, and notable medical complications. A significant unmet need exists for effective and well-tolerated non-pharmacologic acute migraine therapy, according to Alan M. Rapoport, MD.